BLOOD 2023: Zanubrutinib Tied to Improved Progression-Free Survival in Relapsed/Refractory CLL/SLL
The second-generation BTK inhibitor bested ibrutinib, a first-generation BTK inhibitor
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.